-
1.
公开(公告)号:US20200039931A1
公开(公告)日:2020-02-06
申请号:US16601396
申请日:2019-10-14
发明人: Koen VANDYCK , Geerwin Yvonne Paul HACHÉ , Stefaan Julien LAST , David Craig MCGOWAN , Geert ROMBOUTS , Wim Gaston VERSCHUEREN , Pierre Jean-Marie Bernard RABOISSON
IPC分类号: C07D207/36 , A61K45/06 , A61K31/401 , C07D207/40 , C07D403/12 , C07D405/12
摘要: Inhibitors of HBV replication of Formula (ID) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, Ra to Rd and R4 to R6 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
-
公开(公告)号:US20180258074A1
公开(公告)日:2018-09-13
申请号:US15779468
申请日:2016-11-25
发明人: Tim Hugo Maria JONCKERS , David Craig MCGOWAN , Jérôme Émile George GUILLLEMONT , Ludwig Paul COOYMANS , Werner Constant Johan EMBRECHTS , Christophe Francis Robert Nest BUYCK , Wendy Mia Albert BALEMANS , Pierre Jean-Marie Bernard RABOISSON
IPC分类号: C07D403/04 , A61K31/53 , A61K45/06 , C07D403/12 , A61K31/506 , C07D487/04 , C07D417/14 , A61P31/16
CPC分类号: C07D403/04 , A61K31/506 , A61K31/53 , A61K45/06 , A61P31/16 , C07D403/12 , C07D417/14 , C07D487/04
摘要: The current invention relates to a compound of formula (I) which can be used for the treatment of, or against viral influenza infections.
-
3.
公开(公告)号:US20180141905A1
公开(公告)日:2018-05-24
申请号:US15875929
申请日:2018-01-19
发明人: Koen VANDYCK , Geerwin Yvonne Paul HACHÉ , Stefaan Julien LAST , David Craig MCGOWAN , Geert ROMBOUTS , Wim Gaston VERSCHUEREN , Pierre Jean-Marie Bernard RABOISSON
IPC分类号: C07D207/36 , C07D403/12 , C07D405/12 , C07D207/40 , A61K45/06 , A61K31/401
摘要: Inhibitors of HBV replication of Formula (ID) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, Ra to Rd and R4 to R6 have the meaning as defined herein.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
-
-